Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q3 2022 · 10-Q
Revenue—
Net Income-$17.54M-$17.54MN/M vs Q3 2021 EPS Diluted-$0.08-$0.08N/M vs Q3 2021 Operating Income-$17,023,960N/M Operating Cash Flowderived-$21,099,242N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 10, 2022 · 41 d after period end